BNTX Stock — Price, Charts & Analysis

BioNTech SE (BNTX) has no trailing P/E shown and a forward P/E of -19.70x. This places BNTX in not enough valuation data territory based on the valuation data currently available on Worldtickers.

BNTX trades with -19.70x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether BNTX looks overvalued or undervalued.

BNTX's P/E of -19.70x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

BNTX's trailing EPS is -$7.77 and forward EPS is -$5.63.

EPS, or earnings per share, shows how much profit BioNTech SE generated for each share. BNTX's trailing EPS is -$7.77, and investors usually prefer EPS that is positive and growing over time.

BioNTech SE has a market cap of $27.86B, making BNTX a large-cap stock based on the current market value shown on Worldtickers.

BNTX's latest stock price on Worldtickers is $110.89. The latest move is -$2.23 or -1.97%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

BNTX's quote includes a latest price of $110.89. The market open is $109.06. Previous close is $113.12. The intraday range is $106.38 to $112.39.

BNTX is down in the latest quote, with a move of -$2.23 or -1.97%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

BNTX generated $2.65B in trailing revenue. Revenue growth is -59.50%, which helps show whether demand is expanding or slowing.

BNTX's revenue growth is -59.50%, which is a negative demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

No, BNTX does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -$1.69B.

Gross margin is 76.62%. Margins show how efficiently BioNTech SE turns revenue into profit.

BioNTech SE carries $316.10M and holds $13.46B in cash.

BNTX holds $13.46B on its balance sheet.

BNTX's book value per share is $81.83.

Institutions hold 20.36% of BNTX shares. Insiders hold 57.51% of shares. Ownership mix helps investors understand how much of BioNTech SE is held by professional investors and company insiders.

BNTX has 251.2M shares outstanding. Float shares are 108.42M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for BNTX, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for BNTX is -$5.63. Revenue growth is -59.50%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

BNTX's trailing EPS is -$7.77. Forward EPS is -$5.63. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

BNTX is in the Healthcare sector. Its earnings multiple is -19.70x. Its latest displayed growth metric is -59.50%. Compare these figures with sector peers before deciding whether BioNTech SE is stronger or weaker than average.

BNTX trades at $110.89. The stock trades at -19.70x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of BioNTech SE's fundamentals.

BNTX risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 1.28, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

BNTX should be compared with companies in Biotechnology. Its earnings multiple is -19.70x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

BioNTech SE (BNTX) operates in Healthcare, specifically Biotechnology. BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide;

BNTX trades on NasdaqGS. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

BNTX stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

BioNTech SE's official website listed on Worldtickers is www.biontech.de. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

BioNTech SE employs about 7.81K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

BioNTech SE is headquartered in Mainz, Germany. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

BNTX is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

BNTX has traded between $79.52 and $124.00 over the past 52 weeks. At $110.89, it is 10.57% below the high and 39.45% above the low. The 52-week range helps gauge long-term price momentum.

BNTX is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is $92.53 and its 200-day moving average is $97.58.

BNTX's RSI is 74.95. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a overbought momentum setup.

BNTX's latest RSI reading is 74.95, which points to overbought momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for BNTX is near $88.20. Key resistance is near $116.00. Breaks above resistance or below support can change the short-term technical setup.

BNTX's nearest reported support level is $88.20. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

BNTX's nearest reported resistance level is $116.00. A breakout above resistance can improve momentum, especially when volume confirms the move.

BNTX trades about 1.07M shares daily on average. The latest displayed volume is 3.49M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

BNTX's MACD is 1.96, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

BNTX is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 74.95 (overbought). MACD is bullish. Nearest support is around $88.20. Resistance is around $116.00. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $94.05 (17.90% from price). MA50 is $92.53 (19.85% from price). MA200 is $97.58 (13.64% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. BNTX's MA20 is $94.05. MA50 is $92.53. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

BNTX's pivot is near $112.10. Support is near $88.20. Resistance is near $116.00. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for BNTX is near $101.48. The next upper resistance zone is near $120.16. These levels help define risk and possible follow-through zones after a breakout or breakdown.

BNTX's Bollinger range is roughly $81.91 to $106.20. Band width is near 25.83%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

BNTX's ATR-based typical daily range is about 3.79%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 3.49M shares. Average volume is about 1.07M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

BNTX's all-time high shown on Worldtickers is $464.00. Its all-time low is $12.53. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

BNTX has a beta of 1.28, meaning it has historically been more volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.